

# Philippe Moreau

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11831822/philippe-moreau-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

382  
papers

38,201  
citations

100  
h-index

190  
g-index

398  
ext. papers

45,814  
ext. citations

7.9  
avg, IF

6.94  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 382 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e328-e346   | 21.7 | 1155      |
| 381 | Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2863-9   | 2.2  | 976       |
| 380 | Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. <i>American Journal of Hematology</i> , <b>2005</b> , 79, 319-28 | 7.1  | 971       |
| 379 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 621-31   | 59.2 | 935       |
| 378 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1319-1331   | 59.2 | 930       |
| 377 | Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 142-52   | 59.2 | 928       |
| 376 | Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1782-91   | 59.2 | 848       |
| 375 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 431-40  | 21.7 | 731       |
| 374 | Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Mylome. <i>Blood</i> , <b>2007</b> , 109, 3489-95   | 2.2  | 727       |
| 373 | Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1621-34   | 59.2 | 684       |
| 372 | Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1311-1320  | 59.2 | 608       |
| 371 | Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1195-206         | 21.7 | 604       |
| 370 | Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 1055-1066  | 21.7 | 586       |
| 369 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , <b>2012</b> , 26, 149-57  | 10.7 | 580       |
| 368 | Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 27-38  | 21.7 | 576       |
| 367 | Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 906-17  | 59.2 | 565       |
| 366 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. <i>Blood</i> , <b>2006</b> , 108, 3289-94  | 2.2  | 556       |

|     |  |      |     |
|-----|--|------|-----|
| 365 | Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , <b>2016</b> , 127, 2955-62   | 2.2  | 463 |
| 364 | Comparison of 200 mg/m <sup>2</sup> melphalan and 8 Gy total body irradiation plus 140 mg/m <sup>2</sup> melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Mylome 9502                       | 2.2  | 446 |
| 363 | Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4621-9                | 2.2  | 444 |
| 362 | Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 2104-2115   | 59.2 | 435 |
| 361 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , <b>2015</b> , 125, 2068-74  | 2.2  | 426 |
| 360 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , <b>2019</b> , 394, 29-38   | 40   | 383 |
| 359 | High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1083-93  | 59.2 | 383 |
| 358 | Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , <b>2012</b> , 120, 947-59  | 2.2  | 370 |
| 357 | Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3279-3289  | 2.2  | 361 |
| 356 | IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. <i>International Immunology</i> , <b>1999</b> , 11, 803-11   | 4.9  | 340 |
| 355 | Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4630-4  | 2.2  | 336 |
| 354 | Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , <b>2011</b> , 117, 4701-5  | 2.2  | 323 |
| 353 | Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3664-70  | 2.2  | 322 |
| 352 | Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Mylome. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4788-97 | 2.2  | 318 |
| 351 | Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. <i>Blood</i> , <b>2006</b> , 107, 3474-80  | 2.2  | 302 |
| 350 | HLA-G: from biology to clinical benefits. <i>Trends in Immunology</i> , <b>2008</b> , 29, 125-32   | 14.4 | 288 |
| 349 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 705-716  | 59.2 | 287 |
| 348 | Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 207-221   | 21.7 | 281 |

|     |   |      |     |
|-----|---|------|-----|
| 347 | Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. <i>Blood</i> , <b>2017</b> , 130, 2401-2409   | 2.2  | 277 |
| 346 | Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e206-e217   | 21.7 | 275 |
| 345 | HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. <i>Advances in Immunology</i> , <b>2003</b> , 81, 199-252  | 5.6  | 270 |
| 344 | Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. <i>Blood</i> , <b>2001</b> , 97, 1566-71  | 2.2  | 269 |
| 343 | Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1811-1822  | 59.2 | 268 |
| 342 | Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 727-738  | 59.2 | 266 |
| 341 | Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 657-64   | 2.2  | 262 |
| 340 | Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. <i>Blood</i> , <b>2002</b> , 100, 1579-83  | 2.2  | 261 |
| 339 | Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , <b>2008</b> , 111, 3968-77  | 2.2  | 260 |
| 338 | Beyond the increasing complexity of the immunomodulatory HLA-G molecule. <i>Blood</i> , <b>2008</b> , 111, 4862-70  | 2.2  | 256 |
| 337 | International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 587-600                   | 2.2  | 255 |
| 336 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , <b>2019</b> , 394, 2096-2107 | 40   | 253 |
| 335 | Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1327-1337  | 21.7 | 248 |
| 334 | Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1953-9   | 2.2  | 244 |
| 333 | Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. <i>Cellular and Molecular Life Sciences</i> , <b>2011</b> , 68, 369-95  | 10.3 | 240 |
| 332 | Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. <i>Blood</i> , <b>2011</b> , 118, 5752-8; quiz 5982                              | 2.2  | 238 |
| 331 | International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , <b>2011</b> , 117, 6063-73   | 2.2  | 234 |
| 330 | HLA-G: An Immune Checkpoint Molecule. <i>Advances in Immunology</i> , <b>2015</b> , 127, 33-144   | 5.6  | 231 |

|     |  |      |     |
|-----|--|------|-----|
| 329 | Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. <i>Haematologica</i> , <b>2006</b> , 91, 1498-505  | 6.6  | 219 |
| 328 | Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. <i>Blood</i> , <b>2011</b> , 118, 1239-47  | 2.2  | 216 |
| 327 | Prognostic significance of copy-number alterations in multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4585-90  | 2.2  | 216 |
| 326 | HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. <i>Cancer Research</i> , <b>2005</b> , 65, 10139-44   | 10.1 | 207 |
| 325 | Frontline therapy of multiple myeloma. <i>Blood</i> , <b>2015</b> , 125, 3076-84   | 2.2  | 206 |
| 324 | International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1544-57  | 2.2  | 204 |
| 323 | Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My[el]ome. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2712-7  | 2.2  | 203 |
| 322 | Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3279-87  | 2.2  | 199 |
| 321 | Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , <b>2018</b> , 132, 2456-2464  | 2.2  | 191 |
| 320 | Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. <i>British Journal of Haematology</i> , <b>1998</b> , 101, 766-9  | 4.5  | 188 |
| 319 | Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. <i>Blood</i> , <b>2017</b> , 130, 2392-2400  | 2.2  | 182 |
| 318 | Trogocytosis-based generation of suppressive NK cells. <i>EMBO Journal</i> , <b>2007</b> , 26, 1423-33   | 13   | 176 |
| 317 | Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My[el]ome 2009-02. <i>Blood</i> , <b>2013</b> , 121, 1968-75  | 2.2  | 173 |
| 316 | Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2911-2918  | 2.2  | 172 |
| 315 | VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. <i>Blood</i> , <b>2016</b> , 127, 2569-74  | 2.2  | 167 |
| 314 | Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2475-83 | 2.2  | 162 |
| 313 | Prognostic role of circulating exosomal miRNAs in multiple myeloma. <i>Blood</i> , <b>2017</b> , 129, 2429-2436  | 2.2  | 161 |
| 312 | Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1949-52   | 2.2  | 156 |

|     |  |      |     |
|-----|--|------|-----|
| 311 | Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , <b>2016</b> , 127, 681-95  | 2.2  | 154 |
| 310 | Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , <b>2018</b> , 131, 301-310   | 2.2  | 151 |
| 309 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 781-794   | 21.7 | 150 |
| 308 | Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4767-73  | 12.9 | 150 |
| 307 | Current treatment landscape for relapsed and/or refractory multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 42-54   | 19.4 | 146 |
| 306 | CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. <i>Blood</i> , <b>2003</b> , 102, 1070-1   | 2.2  | 141 |
| 305 | The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. <i>Haematologica</i> , <b>2006</b> , 91, 1234-40  | 6.6  | 140 |
| 304 | Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 775-783  | 2.2  | 139 |
| 303 | International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4521-30 <sup>2</sup>  | 2.2  | 136 |
| 302 | Autologous hematopoietic stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2645-54   | 59.2 | 136 |
| 301 | Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 953-964  | 21.7 | 134 |
| 300 | Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , <b>2018</b> , 103, 2088-2096   | 6.6  | 133 |
| 299 | Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5720-6   | 2.2  | 131 |
| 298 | Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 253-264   | 40   | 131 |
| 297 | Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. <i>Lancet Haematology,the</i> , <b>2015</b> , 2, e516-27  | 14.6 | 129 |
| 296 | Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2172-80 | 2.2  | 128 |
| 295 | Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). <i>Blood</i> , <b>2010</b> , 115, 32-7  | 2.2  | 127 |
| 294 | Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1209-14  | 2.2  | 125 |

|     |  |      |     |
|-----|--|------|-----|
| 293 | Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. <i>Haematologica</i> , <b>2010</b> , 95, 311-9  | 6.6  | 123 |
| 292 | Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , <b>2016</b> , 128, 497-503  | 2.2  | 117 |
| 291 | Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1898-906   | 2.2  | 112 |
| 290 | Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1992</b> , 30, 535-41                              | 5.1  | 110 |
| 289 | Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1630-1642           | 21.7 | 110 |
| 288 | Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. <i>Haematologica</i> , <b>2010</b> , 95, 1973-6  | 6.6  | 109 |
| 287 | Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. <i>Haematologica</i> , <b>2012</b> , 97, 1925-8  | 6.6  | 108 |
| 286 | How I treat extramedullary myeloma. <i>Blood</i> , <b>2016</b> , 127, 971-6  | 2.2  | 103 |
| 285 | PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. <i>Blood</i> , <b>2014</b> , 124, 1626-36   | 2.2  | 101 |
| 284 | Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 896-905                  | 4.5  | 101 |
| 283 | Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. <i>Haematologica</i> , <b>2008</b> , 93, 1908-11   | 6.6  | 100 |
| 282 | Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. <i>Blood</i> , <b>2011</b> , 117, 2009-11   | 2.2  | 99  |
| 281 | Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. <i>Blood</i> , <b>2010</b> , 116, 4777-82   | 2.2  | 99  |
| 280 | Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , <b>2016</b> , 127, 713-21   | 2.2  | 99  |
| 279 | Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. <i>Lancet Haematology,the</i> , <b>2020</b> , 7, e370-e380                      | 14.6 | 98  |
| 278 | Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology,the</i> , <b>2016</b> , 3, e506-e515 | 14.6 | 98  |
| 277 | Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. <i>Blood</i> , <b>2011</b> , 117, 3041-4   | 2.2  | 98  |
| 276 | Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 109   | 7    | 97  |

|     |  |      |    |
|-----|--|------|----|
| 275 | Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative autotransplantation with autologous transplantation in high-risk de novo multiple myeloma. <i>Blood</i> , <b>2008</b> , 112, 3914-5 | 2.2  | 96 |
| 274 | Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , <b>2018</b> , 32, 2604-2616   | 10.7 | 90 |
| 273 | ABT-737 is highly effective against molecular subgroups of multiple myeloma. <i>Blood</i> , <b>2011</b> , 118, 3901-102.2  | 2.2  | 89 |
| 272 | Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, 1095-104                                | 5.9  | 87 |
| 271 | Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , <b>2016</b> , 128, 1174-80  | 2.2  | 86 |
| 270 | Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. <i>Seminars in Cancer Biology</i> , <b>2007</b> , 17, 413-21   | 12.7 | 85 |
| 269 | Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du mylome experience. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2806-9         | 2.2  | 84 |
| 268 | HLA-G gene polymorphism in human placentas: possible association of G*0106 allele with preeclampsia and miscarriage. <i>Biology of Reproduction</i> , <b>2008</b> , 79, 459-67   | 3.9  | 82 |
| 267 | Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. <i>Blood</i> , <b>2006</b> , 107, 397-403                           | 2.2  | 81 |
| 266 | Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>Blood</i> , <b>2019</b> , 134, 421-431   | 2.2  | 80 |
| 265 | Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , <b>2015</b> , 126, 391-391                      | 2.2  | 80 |
| 264 | Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. <i>Blood</i> , <b>2015</b> , 125, 1411-7  | 2.2  | 78 |
| 263 | European perspective on multiple myeloma treatment strategies in 2014. <i>Oncologist</i> , <b>2014</b> , 19, 829-44  | 5.7  | 77 |
| 262 | Non-classical transcriptional regulation of HLA-G: an update. <i>Journal of Cellular and Molecular Medicine</i> , <b>2009</b> , 13, 2973-89  | 5.6  | 77 |
| 261 | Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. <i>Leukemia</i> , <b>2020</b> , 34, 1875-1884              | 10.7 | 77 |
| 260 | Targeting Bcl-2 for the treatment of multiple myeloma. <i>Leukemia</i> , <b>2018</b> , 32, 1899-1907   | 10.7 | 72 |
| 259 | The dual role of HLA-G in cancer. <i>Journal of Immunology Research</i> , <b>2014</b> , 2014, 359748   | 4.5  | 72 |
| 258 | Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?. <i>Blood</i> , <b>2015</b> , 126, 2713-9   | 2.2  | 71 |



|     |  |      |    |
|-----|--|------|----|
| 257 | Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , <b>2020</b> , 34, 2000-2011   | 10.7 | 71 |
| 256 | Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , <b>2017</b> , 130, 2610-2618   | 2.2  | 69 |
| 255 | Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. <i>Clinical Pharmacokinetics</i> , <b>2012</b> , 51, 823-9   | 6.2  | 68 |
| 254 | Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. <i>Blood</i> , <b>2015</b> , 125, 2095-100   | 2.2  | 64 |
| 253 | Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , <b>2019</b> , 133, 1953-1963  | 2.2  | 63 |
| 252 | Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , <b>2015</b> , 100, 1327-33  | 6.6  | 63 |
| 251 | Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology</i> , <b>2018</b> , 5, e563-e598  | 14.6 | 62 |
| 250 | Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. <i>Blood</i> , <b>2019</b> , 134, 668-677   | 2.2  | 59 |
| 249 | FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. <i>Haematologica</i> , <b>2008</b> , 93, 1269-71  | 6.6  | 58 |
| 248 | Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3921-3930 | 2.2  | 58 |
| 247 | RREB-1 is a transcriptional repressor of HLA-G. <i>Journal of Immunology</i> , <b>2009</b> , 183, 6948-59  | 5.3  | 54 |
| 246 | A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. <i>Leukemia</i> , <b>2020</b> , 34, 224-233  | 10.7 | 54 |
| 245 | How I treat myeloma with new agents. <i>Blood</i> , <b>2017</b> , 130, 1507-1513   | 2.2  | 53 |
| 244 | Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1657-1665  | 2.2  | 51 |
| 243 | Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. <i>Haematologica</i> , <b>2016</b> , 101, 1390-1397   | 6.6  | 51 |
| 242 | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 404-413   | 4.5  | 50 |
| 241 | Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. <i>Cancer Research</i> , <b>2012</b> , 72, 4562-73  | 10.1 | 50 |
| 240 | Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 445-9   | 4.7  | 49 |

|     |   |      |    |
|-----|---|------|----|
| 239 | Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1389-1397   | 13.4 | 48 |
| 238 | Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies. <i>Blood</i> , <b>2013</b> , 122, 767-767 | 2.2  | 48 |
| 237 | The effects of bortezomib on bone disease in patients with multiple myeloma. <i>Cancer</i> , <b>2014</b> , 120, 618-236.4   | 4    | 47 |
| 236 | The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. <i>Seminars in Hematology</i> , <b>2012</b> , 49 Suppl 1, S33-46  | 4    | 47 |
| 235 | Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. <i>Haematologica</i> , <b>2011</b> , 96, 1504-11             | 6.6  | 46 |
| 234 | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 2361-2371   | 40   | 46 |
| 233 | Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 737-48  | 3.5  | 43 |
| 232 | Immunophenotype of normal and myelomatous plasma-cell subsets. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 137  | 8.4  | 43 |
| 231 | European perspective on multiple myeloma treatment strategies: update following recent congresses. <i>Oncologist</i> , <b>2012</b> , 17, 592-606  | 5.7  | 43 |
| 230 | Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial. <i>Blood</i> , <b>2015</b> , 126, 191-191                                      | 2.2  | 43 |
| 229 | Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. <i>Blood Advances</i> , <b>2018</b> , 2, 1633-1644  | 7.8  | 43 |
| 228 | CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. <i>Leukemia Research</i> , <b>2008</b> , 32, 379-82  | 2.7  | 42 |
| 227 | Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , <b>2015</b> , 125, 3100-4   | 2.2  | 41 |
| 226 | Lack of CD27 in myeloma delineates different presentation and outcome. <i>British Journal of Haematology</i> , <b>2006</b> , 132, 168-70  | 4.5  | 41 |
| 225 | Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection. <i>Cancer</i> , <b>1993</b> , 72, 3223-6  | 6.4  | 41 |
| 224 | Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3252-3260   | 2.2  | 41 |
| 223 | Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , <b>2018</b> , 32, 1542-1560   | 10.7 | 40 |
| 222 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 571-582   | 4.5  | 39 |

|     |  |      |    |
|-----|--|------|----|
| 221 | Multiple myeloma: from front-line to relapsed therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015</i> , e504-11  | 7.1  | 39 |
| 220 | A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology, 2017</i> , 178, 547-560 | 4.5  | 38 |
| 219 | Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. <i>Blood Cancer Journal, 2019</i> , 9, 38  | 7    | 37 |
| 218 | Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology, 2017</i> , 10, 137                                      | 22.4 | 37 |
| 217 | Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥5 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01.. <i>Blood, 2007</i> , 110, 75-75    | 2.2  | 37 |
| 216 | Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. <i>Blood, 2018</i> , 132, 2555-2563   | 2.2  | 37 |
| 215 | BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. <i>Blood, 2018</i> , 132, 2656-2669  | 2.2  | 37 |
| 214 | Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia, 2018</i> , 18, e401-e419   | 2    | 37 |
| 213 | Timing the initiation of multiple myeloma. <i>Nature Communications, 2020</i> , 11, 1917   | 17.4 | 36 |
| 212 | Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica, 2017</i> , 102, 1767-1775                                 | 6.6  | 36 |
| 211 | Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal, 2020</i> , 10, 91   | 7    | 36 |
| 210 | Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02.. <i>Blood, 2010</i> , 116, 310-310   | 2.2  | 35 |
| 209 | Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The, 2021</i> , 22, 801-812   | 21.7 | 35 |
| 208 | Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Haematologica, 2015</i> , 100, 1334-9                    | 6.6  | 34 |
| 207 | Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. <i>Future Oncology, 2020</i> , 16, 4347-4358   | 3.6  | 34 |
| 206 | Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. <i>British Journal of Haematology, 2017</i> , 179, 198-218   | 4.5  | 33 |
| 205 | Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology, The, 2021</i> , 22, e119-e130  | 21.7 | 33 |
| 204 | Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). <i>Haematologica, 2017</i> , 102, e112-e114   | 6.6  | 32 |

|     |   |      |    |
|-----|---|------|----|
| 203 | Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e105-e118  | 21.7 | 32 |
| 202 | A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4350-4355   | 12.9 | 32 |
| 201 | Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. <i>Leukemia</i> , <b>2018</b> , 32, 2626-2635   | 10.7 | 31 |
| 200 | Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 985                   | 7.1  | 31 |
| 199 | Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, 519-30 | 2    | 31 |
| 198 | Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , <b>2021</b> , 35, 562-572   | 10.7 | 31 |
| 197 | Standardization of F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 116-125   | 2.2  | 31 |
| 196 | Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 783-795  | 4.5  | 30 |
| 195 | Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , <b>2020</b> , 34, 2430-2440   | 10.7 | 30 |
| 194 | HLA-G expression in the skin of patients with systemic sclerosis. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1230-4   | 4    | 30 |
| 193 | Lenalidomide: a new therapy for multiple myeloma. <i>Cancer Treatment Reviews</i> , <b>2008</b> , 34, 283-91  | 14.4 | 30 |
| 192 | Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. <i>Haematologica</i> , <b>2015</b> , 100, e56-9   | 6.6  | 29 |
| 191 | IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. <i>Journal of Immunology</i> , <b>2008</b> , 181, 6837-42   | 5.3  | 29 |
| 190 | Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 522-530.e1  | 2    | 28 |
| 189 | Revealing the impact of structural variants in multiple myeloma. <i>Blood Cancer Discovery</i> , <b>2020</b> , 1, 258-273   | 3    | 28 |
| 188 | A predictive model for risk of early grade B infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , <b>2018</b> , 32, 1404-1413  | 10.7 | 28 |
| 187 | How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 112, 153-170  | 7    | 27 |
| 186 | Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. <i>Haematologica</i> , <b>2015</b> , 100, e207-10   | 6.6  | 27 |

|     |  |      |    |
|-----|--|------|----|
| 185 | Multiple myeloma--translation of trial results into reality. <i>Lancet, The</i> , <b>2016</b> , 388, 111-3   | 40   | 27 |
| 184 | Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). <i>Blood</i> , <b>2015</b> , 126, 727-727 | 2.2  | 26 |
| 183 | Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , <b>2016</b> , 76, 853-67   | 12.1 | 26 |
| 182 | Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 11, 49               | 22.4 | 25 |
| 181 | Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 418-427  | 7.1  | 25 |
| 180 | Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 229-237   | 2.8  | 24 |
| 179 | Daratumumab for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 887-893   | 5.4  | 23 |
| 178 | Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 23   | 7    | 23 |
| 177 | The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , <b>2015</b> , 11, 1153-68  | 3.6  | 23 |
| 176 | Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2833-2838   | 1.9  | 23 |
| 175 | Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. <i>Haematologica</i> , <b>2014</b> , 99, 1236-8  | 6.6  | 23 |
| 174 | Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1139-1149   | 2.2  | 23 |
| 173 | The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. <i>Nature Immunology</i> , <b>2021</b> , 22, 769-780   | 19.1 | 23 |
| 172 | Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , <b>2019</b> , 3, e163   | 0.3  | 23 |
| 171 | Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. <i>Blood Cells, Molecules, and Diseases</i> , <b>2012</b> , 48, 247-53  | 2.1  | 22 |
| 170 | Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , <b>2015</b> , 126, 28-28  | 2.2  | 22 |
| 169 | Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 142-154   | 21.7 | 22 |
| 168 | IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 746-751  | 7.1  | 21 |

|     |   |      |    |
|-----|---|------|----|
| 167 | Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. <i>Annals of Hematology</i> , <b>2019</b> , 98, 1435-1440   | 3    | 21 |
| 166 | Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. <i>Blood</i> , <b>2016</b> , 128, 488-488  | 2.2  | 21 |
| 165 | Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2165-73                         | 1.9  | 20 |
| 164 | An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 176-176  | 2.2  | 20 |
| 163 | Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1546-59  | 1.9  | 19 |
| 162 | Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 35-48  | 3.8  | 19 |
| 161 | Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , <b>2017</b> , 117, 185-191   | 10.2 | 19 |
| 160 | PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,   | 6.3  | 19 |
| 159 | Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. <i>Haematologica</i> , <b>2015</b> , 100, e63-7                                     | 6.6  | 19 |
| 158 | The emerging role of carfilzomib combination therapy in the management of multiple myeloma. <i>Expert Review of Hematology</i> , <b>2014</b> , 7, 265-90  | 2.8  | 19 |
| 157 | Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAiA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1582-1596    | 21.7 | 19 |
| 156 | Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , <b>2021</b> , 5, e528   | 0.3  | 19 |
| 155 | Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3107-3118  | 2.2  | 19 |
| 154 | del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. <i>Blood</i> , <b>2021</b> , 137, 1192-1195  | 2.2  | 19 |
| 153 | Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. <i>Haematologica</i> , <b>2016</b> , 101, 872-8                    | 6.6  | 18 |
| 152 | Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. <i>Experimental Hematology</i> , <b>2013</b> , 41, 1008-15                              | 3.1  | 18 |
| 151 | Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant. <i>Blood</i> , <b>2018</b> , 132, 595-595 | 2.2  | 18 |
| 150 | Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. <i>Recent Results in Cancer Research</i> , <b>2011</b> , 183, 189-206   | 1.5  | 18 |

|     |   |      |    |
|-----|---|------|----|
| 149 | Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , <b>2021</b> , 35, 1722-1731   | 10.7 | 18 |
| 148 | Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. <i>Journal of Hematology and Oncology</i> , <b>2018</b> , 11, 137                   | 22.4 | 18 |
| 147 | Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2430-2442          | 2.2  | 18 |
| 146 | Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. <i>Cancer Biology and Therapy</i> , <b>2015</b> , 16, 60-5   | 4.6  | 17 |
| 145 | New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. <i>Journal of Blood Medicine</i> , <b>2017</b> , 8, 107-121  | 2.3  | 17 |
| 144 | Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma. <i>Oncotarget</i> , <b>2015</b> , 6, 26922-34   | 3.3  | 17 |
| 143 | Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2501-2504     | 1.9  | 16 |
| 142 | Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of SUVmax in the FDG-Avid Patients of the IMAJEM Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5219-5224  | 12.9 | 16 |
| 141 | Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patientsN selection and perspective. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 5813-5822   | 4.4  | 16 |
| 140 | Logic programming reveals alteration of key transcription factors in multiple myeloma. <i>Scientific Reports</i> , <b>2017</b> , 7, 9257  | 4.9  | 16 |
| 139 | Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , <b>2021</b> , 137, 3616-3628  | 2.2  | 16 |
| 138 | Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. <i>Haematologica</i> , <b>2016</b> , 101, 356-62 | 6.6  | 16 |
| 137 | Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). <i>Haematologica</i> , <b>2021</b> , 106, 1725-1732                                    | 6.6  | 16 |
| 136 | Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 207-215  | 2.8  | 15 |
| 135 | Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 199-206                               | 3.8  | 15 |
| 134 | Interest of Pet Imaging in Multiple Myeloma. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 69   | 4.9  | 15 |
| 133 | A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 121, 74-89   | 7    | 15 |
| 132 | RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway. <i>BMC Cancer</i> , <b>2014</b> , 14, 437  | 4.8  | 15 |

|     |  |      |    |
|-----|--|------|----|
| 131 | Stem-cell transplantation in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , <b>2005</b> , 18, 603-18  | 4.2  | 15 |
| 130 | Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1378-1390 | 21.7 | 15 |
| 129 | First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2308-2317   | 12.9 | 14 |
| 128 | Oral therapy for multiple myeloma: ixazomib arriving soon. <i>Blood</i> , <b>2014</b> , 124, 986-7   | 2.2  | 14 |
| 127 | Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. <i>Haematologica</i> , <b>2014</b> , 99, e33-4   | 6.6  | 14 |
| 126 | Safety of ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 973-980   | 2.2  | 14 |
| 125 | Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3602-3612  | 2.2  | 14 |
| 124 | Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m vs. twice-weekly 27 mg/m carfilzomib (randomized A.R.R.O.W. study). <i>Leukemia</i> , <b>2019</b> , 33, 2934-2946   | 10.7 | 13 |
| 123 | Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 316   | 9.8  | 13 |
| 122 | Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergrupe Francophone du Myelome. <i>European Journal of Haematology</i> , <b>2012</b> , 88, 249-59  | 3.8  | 13 |
| 121 | Bortezomib Plus Dexamethasone (VD) Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexamethasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).. <i>Blood</i> , <b>2009</b> , 114, 354-354   | 2.2  | 13 |
| 120 | Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 319-327  | 4.5  | 12 |
| 119 | Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 66-74  | 4.5  | 12 |
| 118 | Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma. <i>Frontiers in Physiology</i> , <b>2017</b> , 8, 149  | 4.6  | 12 |
| 117 | All transplantation-eligible patients with myeloma should receive ASCT in first response. <i>Hematology American Society of Hematology Education Program</i> , <b>2014</b> , 2014, 250-4   | 3.1  | 12 |
| 116 | The translocation t(4;14) can be present only in minor subclones in multiple myeloma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4634-7   | 12.9 | 12 |
| 115 | Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?. <i>Transplantation</i> , <b>2012</b> , 94, 295-301  | 1.8  | 12 |
| 114 | Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , <b>2015</b> , 126, 395-395  | 2.2  | 12 |



|     |   |      |    |
|-----|---|------|----|
| 113 | Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment. <i>Oncotarget</i> , <b>2015</b> , 6, 37385-97   | 3.3  | 12 |
| 112 | Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 496-507   | 4.5  | 12 |
| 111 | p53 regulates CD46 expression and measles virus infection in myeloma cells. <i>Blood Advances</i> , <b>2018</b> , 2, 3492-3505  | 7.8  | 12 |
| 110 | The Autoimmune Regulator (Aire) transactivates HLA-G gene expression in thymic epithelial cells. <i>Immunology</i> , <b>2019</b> , 158, 121-135   | 7.8  | 11 |
| 109 | Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study. <i>Blood</i> , <b>2010</b> , 116, 624-624 | 2.2  | 11 |
| 108 | Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 302-302   | 2.2  | 11 |
| 107 | The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. <i>Advances in Therapy</i> , <b>2016</b> , 33, 1896-1920   | 4.1  | 11 |
| 106 | Leveraging RSF and PET images for prognosis of multiple myeloma at diagnosis. <i>International Journal of Computer Assisted Radiology and Surgery</i> , <b>2020</b> , 15, 129-139   | 3.9  | 11 |
| 105 | Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. <i>Annals of Hematology</i> , <b>2019</b> , 98, 1441-1447  | 3.4  | 10 |
| 104 | Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , <b>2019</b> , 186, e35-e39                        | 4.5  | 10 |
| 103 | Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 35   | 7    | 10 |
| 102 | PET-CT in MM: a new definition of CR. <i>Blood</i> , <b>2011</b> , 118, 5984-5  | 2.2  | 10 |
| 101 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , <b>2022</b> ,   | 21.7 | 10 |
| 100 | Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 8542-8542  | 2.2  | 10 |
| 99  | Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8002-8002  | 2.2  | 10 |
| 98  | Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. <i>Leukemia</i> , <b>2019</b> , 33, 313-318  | 10.7 | 10 |
| 97  | Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia Research</i> , <b>2019</b> , 83, 106172   | 2.7  | 9  |
| 96  | Once-weekly (70 mg/m <sup>2</sup> ) vs twice-weekly (56 mg/m <sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. <i>Cancer Medicine</i> , <b>2020</b> , 9, 2989-2996                                     | 4.8  | 9  |

|    |   |      |   |
|----|---|------|---|
| 95 | Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation. <i>Journal of Cancer</i> , <b>2014</b> , 5, 248-52   | 4.5  | 9 |
| 94 | Elotuzumab for the treatment of multiple myeloma. <i>Future Oncology</i> , <b>2014</b> , 10, 949-56   | 3.6  | 9 |
| 93 | Frontline treatment of multiple myeloma in elderly patients. <i>Blood Reviews</i> , <b>2008</b> , 22, 303-9   | 11.1 | 9 |
| 92 | Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM). <i>Blood</i> , <b>2013</b> , 122, 3187-3187  | 2.2  | 9 |
| 91 | Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 1005-1015 | 8.8  | 9 |
| 90 | The role of SLAMF7 in multiple myeloma: impact on therapy. <i>Expert Review of Clinical Immunology</i> , <b>2017</b> , 13, 67-75  | 5.1  | 8 |
| 89 | Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 462-470   | 1.9  | 8 |
| 88 | Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. <i>International Journal of Hematology</i> , <b>2019</b> , 110, 466-473                              | 2.3  | 8 |
| 87 | Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , <b>2012</b> , 36 Suppl 1, S13-8   | 2.7  | 8 |
| 86 | Role of HLA-G in innate immunity through direct activation of NF-kappaB in natural killer cells. <i>Molecular Immunology</i> , <b>2008</b> , 45, 419-27   | 4.3  | 8 |
| 85 | Evolving role of stem cell transplantation in multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , <b>2005</b> , 6, 89-95   |      | 8 |
| 84 | Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies. <i>Blood</i> , <b>2012</b> , 120, 749-749  | 2.2  | 8 |
| 83 | Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2839-2847                       | 1.9  | 8 |
| 82 | Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , <b>2018</b> , 32, 2032-2036   | 10.7 | 7 |
| 81 | Pomalidomide in the management of relapsed multiple myeloma. <i>Future Oncology</i> , <b>2016</b> , 12, 1975-83   | 3.6  | 7 |
| 80 | Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. <i>Journal of Medical Economics</i> , <b>2018</b> , 21, 793-798                                 | 2.4  | 7 |
| 79 | Initial treatment of transplant candidates with multiple myeloma. <i>Seminars in Oncology</i> , <b>2013</b> , 40, 585-91  | 5.5  | 7 |
| 78 | Stem cell transplantation in multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , <b>2007</b> , 2007, 311-6   | 3.1  | 7 |

|    |  |      |   |
|----|--|------|---|
| 77 | Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 3309-3309                        | 2.2  | 7 |
| 76 | Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 222-225  | 1.9  | 7 |
| 75 | Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1323-1333   | 1.9  | 6 |
| 74 | Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 1364-1374   | 1.9  | 6 |
| 73 | Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02).. <i>Blood</i> , <b>2009</b> , 114, 529-529   | 2.2  | 6 |
| 72 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , <b>2020</b> , 7, e374-383 | 14.6 | 6 |
| 71 | Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 59  | 22.4 | 6 |
| 70 | New insights in the treatment of patients with solitary bone plasmacytoma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2810-2813  | 1.9  | 5 |
| 69 | Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. <i>Leukemia</i> , <b>2020</b> , 34, 3019-3027   | 10.7 | 5 |
| 68 | Ixazomib in the management of relapsed multiple myeloma. <i>Future Oncology</i> , <b>2018</b> , 14, 2013-2020  | 3.6  | 5 |
| 67 | A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma. <i>Blood</i> , <b>2010</b> , 116, 312-312  | 2.2  | 5 |
| 66 | Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8526-8526                             | 2.2  | 5 |
| 65 | Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,   | 6.3  | 5 |
| 64 | Newly Diagnosed Myeloma in 2020. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , 40, 1-15   | 7.1  | 5 |
| 63 | Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. <i>Blood</i> , <b>2021</b> ,   | 2.2  | 5 |
| 62 | LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.. <i>Leukemia</i> , <b>2022</b> ,  | 10.7 | 5 |
| 61 | Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e228-e237  | 2    | 4 |
| 60 | ImmunoPET in Multiple Myeloma-What? So What? Now What?.. <i>Cancers</i> , <b>2020</b> , 12,  | 6.6  | 4 |

|    |   |     |   |
|----|---|-----|---|
| 59 | c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 35-46  | 3.8 | 4 |
| 58 | Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. <i>Advances in Therapy</i> , <b>2020</b> , 37, 1464-1478   | 4.7 | 4 |
| 57 | Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1850-1859   | 1.9 | 4 |
| 56 | Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation. <i>Hematology/Oncology Clinics of North America</i> , <b>2014</b> , 28, 829-38   | 3.1 | 4 |
| 55 | Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , <b>2009</b> , 9, 885-90  | 3.5 | 4 |
| 54 | Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , <b>2022</b> , 7, 100403   | 6   | 4 |
| 53 | Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 2120-2120 | 2.2 | 4 |
| 52 | Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. <i>Blood</i> , <b>2015</b> , 126, 1844-1844  | 2.2 | 4 |
| 51 | Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2254-2260   | 4.4 | 4 |
| 50 | Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. <i>Cancers</i> , <b>2020</b> , 12,   | 6.6 | 4 |
| 49 | Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. <i>Blood</i> , <b>2021</b> , 138, 113-121  | 2.2 | 4 |
| 48 | Role of the HLA-G immune checkpoint molecule in pregnancy. <i>Human Immunology</i> , <b>2021</b> , 82, 353-361  | 2.3 | 4 |
| 47 | Monoclonal antibodies as an addition to current myeloma therapy strategies. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 33-43  | 3.5 | 4 |
| 46 | Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. <i>Immunotherapy</i> , <b>2021</b> , 13, 143-154   | 3.8 | 4 |
| 45 | Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 30, 965-973  | 5.9 | 4 |
| 44 | Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 111   | 7   | 3 |
| 43 | Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1793-1804   | 3   | 3 |
| 42 | Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF- $\kappa$ B pathway activation. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 274-285  | 3.8 | 3 |

|    |  |      |   |
|----|--|------|---|
| 41 | Role of bone marrow transplantation in the disease pathway of myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2007</b> , 5, 163-9   | 7.3  | 3 |
| 40 | Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. <i>Haematologica</i> , <b>2021</b> , 106, 2257-2260 | 6.6  | 3 |
| 39 | Carfilzomib versus bortezomib for relapsed or refractory myeloma - Authors'Reply. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, e126   | 21.7 | 3 |
| 38 | Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 395-399   | 4.4  | 3 |
| 37 | Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. <i>Leukemia</i> , <b>2021</b> , 35, 1732-1744   | 10.7 | 3 |
| 36 | Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>American Journal of Hematology</i> , <b>2021</b> , 96, E423-E427   | 7.1  | 3 |
| 35 | Extramedullary disease in multiple myeloma: a systematic literature review.. <i>Blood Cancer Journal</i> , <b>2022</b> , 12, 45  | 7    | 3 |
| 34 | Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France. <i>Annals of Hematology</i> , <b>2016</b> , 95, 1307-13   | 3    | 2 |
| 33 | FDG PET in Multiple Myeloma <b>2019</b> , 27-38  |      | 2 |
| 32 | Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 411-5  | 7.5  | 2 |
| 31 | Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. <i>Leukemia</i> , <b>2021</b> , 35, 3600-3603  | 10.7 | 2 |
| 30 | Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. <i>EJHaem</i> , <b>2021</b> , 2, 48-55   | 0.9  | 2 |
| 29 | Global Approaches in Myeloma: Critical Trials That May Change Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 656-661                                 | 7.1  | 2 |
| 28 | Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101217  | 2.2  | 2 |
| 27 | The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. <i>BMC Cancer</i> , <b>2019</b> , 19, 855   | 4.8  | 1 |
| 26 | DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. <i>Clinical Epigenetics</i> , <b>2020</b> , 12, 163   | 7.7  | 1 |
| 25 | FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients??. <i>Cancers</i> , <b>2020</b> , 12,  | 6.6  | 1 |
| 24 | Treatment of Relapsed/Refractory Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , <b>2018</b> , 73-96   | 0    | 1 |

|    |  |      |   |
|----|--|------|---|
| 23 | Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 583-589   | 1.9  | 1 |
| 22 | Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 19,   | 6.3  | 1 |
| 21 | VI. Autologous stem cell transplantation and maintenance therapy. <i>Hematological Oncology</i> , <b>2013</b> , 31 Suppl 1, 42-6   | 1.3  | 1 |
| 20 | Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. <i>Blood</i> , <b>2018</b> , 132, 1960-1960 | 2.2  | 1 |
| 19 | Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. <i>Future Oncology</i> , <b>2021</b> , 17, 993-998   | 3.6  | 1 |
| 18 | No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 635-638   | 4.5  | 1 |
| 17 | The DNA methylation landscape of multiple myeloma shows extensive inter- and inpatient heterogeneity that fuels transcriptomic variability. <i>Genome Medicine</i> , <b>2021</b> , 13, 127   | 14.4 | 1 |
| 16 | Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , <b>2021</b> , 21, 993   | 4.8  | 1 |
| 15 | Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISM by clinical characteristics. <i>European Journal of Haematology</i> , <b>2022</b> , 108, 73-83  | 3.8  | 1 |
| 14 | Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.. <i>Blood</i> , <b>2022</b> , 139, 2747-2757   | 2.2  | 1 |
| 13 | Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. <i>American Journal of Hematology</i> ,   | 7.1  | 1 |
| 12 | Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. <i>Expert Review of Hematology</i> , <b>2021</b> , 1-16  | 2.8  | 0 |
| 11 | The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , <b>2022</b> , 6, e726   | 0.3  | 0 |
| 10 | F-FDG PET/CT in multiple myeloma: critical insights and future directions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1048-1050   | 8.8  |   |
| 9  | Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. <i>Annals of Hematology</i> , <b>2018</b> , 97, 831-837  | 3    |   |
| 8  | Ultra high-risk myeloma: definition, identification, management. <i>Hematologie</i> , <b>2011</b> , 17, 145-149  | 0    |   |
| 7  | RIC alloSCT in MM: a long way to go. <i>Blood</i> , <b>2011</b> , 118, 2378-9  | 2.2  |   |
| 6  | Reply to J.C. Regelinck et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e744-e745   | 2.2  |   |

|   |   |     |
|---|---|-----|
| 5 | Hematopoietic cell transplantation in multiple myeloma. <i>Current Opinion in Organ Transplantation</i> , <b>2004</b> , 9, 39-42  | 2.5 |
| 4 | Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. <i>EJHaem</i> , <b>2020</b> , 1, 481-488               | 0.9 |
| 3 | Multiple myeloma triplet therapies: baseline characteristics and control groups - AuthorsNepley. <i>Lancet, The</i> , <b>2021</b> , 397, 1621-1623  | 4.0 |
| 2 | Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching. <i>EJHaem</i> , <b>2021</b> , 2, 66-80 | 0.9 |
| 1 | An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.. <i>Therapeutic Advances in Hematology</i> , <b>2022</b> , 13, 20406207221088458  | 5.7 |